PIA Executive Committee:
Chair: Douglas Galasko, MD
Dr. Douglas Galasko is a clinician-researcher whose research spans Alzheimer’s Disease, Parkinson’s Disease and other disorders resulting in cognitive impairment and dementia. He currently serves as Associate Director of the UCSD Shiley-Marcos Alzheimer's Disease Research Center (ADRC). He is a member of the Alzheimer’s Disease Cooperative Study, a NIH-funded consortium of medical Centers that conducts clinical trials in Alzheimer’s Disease.
In clinical practice, he provides expert evaluation and comprehensive care for patients with memory and cognitive disorders, including Alzheimer’s Disease, Frontotemporal Dementia, Progressive Aphasia, and Dementia with Lewy Bodies, at the UCSD Perlman Neurology Clinic. He also is a Staff Physician in the Neurology Service of the VA Medical Center, La Jolla, where he sees patients with a variety of neurological disorders.
Dr. Galasko has made research contributions in the area of Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and other disorders associated with cognitive impairment and dementia. He has helped to develop diagnostic criteria for AD, DLB and behavioral variant FTD, and has contributed to the International Working Group (IWG) criteria for terminology of Alzheimer;’s Disease in relation to biomarkers. He has authored over 300 journal articles, over 30 book chapters, and serves as Co-Editor of the journal Alzheimer’s Research and Therapy. Many of his publications are in areas such as cognitive characterization of MCI, DLB, and the relationship between cognition and function. He has served on committees to develop diagnostic criteria for Dementia with Lewy Bodies and to standardize biological sample collection for multicenter research studies.
He has received research funding from the National Institute on Aging, the State of California, the Alzheimer Association, the Michael J Fox Foundation and the Alzheimer’s Disease Drug Discovery Foundation. He also has conducted clinical trials with funding from Pfizer, Elan, Eli Lilly, Biogen and other companies.
He serves as a grant reviewer for the National Institutes of Health, the Veterans Administration, the Michael J Fox Foundation, the Bright Focus Foundation, and the American Federation for Aging Research. He serves on advisory boards for academic research groups and pharmaceutical companies.
Vice Chair: Mark Bondi, PhD
Mark Bondi received his PhD in clinical psychology and neuropsychology in 1991 from the University of Arizona. He completed his internship and postdoctoral fellowship training at UC San Diego and joined the faculty in 1994. He is currently Professor of Psychiatry at UC San Diego and Director of the Neuropsychological Assessment Unit at the VA San Diego Healthcare System. He has served on several elected boards of the American Psychological Association, the Board of Directors of the American Board of Clinical Neuropsychology, and Board of Governors of the International Neuropsychological Society. Since 1998 he has been board certified in Clinical Neuropsychology by the American Board of Professional Psychology. Since 1991 he has received continuous funding from NIH, VA, Alzheimer's Association and private foundation grants, a Mid-Career Investigator Award in Patient-Oriented Research from NIA, and sponsored 18 NIH and VA career development awards of his current and former trainees. His research centers on the cognitive and brain changes of individuals at risk for dementia, and he has published more than 195 articles, books, and book chapters. He serves on the editorial boards of several journals, including the Journal of the International Neuropsychological Society, Neuropsychology, and as an Associate Editor of the Journal of Alzheimer's Disease. He is a Fellow of the American Psychological Association and National Academy of Neuropsychology, and former President of the Society for Clinical Neuropsychology (Division 40 of APA).
Programs Chair: Mathew Summers, PhD
Mathew Summers is a tenured Associate Professor of Psychology at the University of the Sunshine Coast, having previously held positions of Associate Professor of Neuropsychology and Mental Health at the Sunshine Coast Mind and Neuroscience – Thompson Institute and as Senior Research Fellow with the Wicking Dementia Research and Education Centre at the University of Tasmania. A/Prof Summers leads research in dementia and aging an is co-project lead of the Tasmanian Healthy Brain Project, an NHMRC funded project (2011-2020) and is principal investigator on a European Commission HORIZON-2020 consortium and NHMRC funded project, My Active and Healthy Aging (2016-2020). A/Prof Summers has led research to enhance the accuracy pre-dementia (mild cognitive impairment) diagnosis, examine the efficacy of non-pharmacological treatments for age related cognitive decline, and a multi-centre pharmacological trial to enhance cognitive function in Down Syndrome. A/Prof Summers has received in excess of AU$10 million in research funding and has more than 140 publications including 60 international peer-reviewed scientific papers. He has over 20 years of clinical practice as a Clinical Neuropsychologist and is a Fellow of the APS College of Clinical Neuropsychologists and member of the International Neuropsychological Society. A/Prof Summers has provided expert evidence as a neuropsychologist to the Federal Court of Australia, Supreme Court of Tasmania, Family Court of Australia, and Magistrates Court of Tasmania.
Communications Chair: Roos Jutten, PhD
Roos Jutten is a neuropsychologist at the Alzheimer Center Amsterdam (Amsterdam UMC, The Netherlands). In 2014, she obtained her master’s degree in Clinical Neuropsychology and after that she started her PhD project. She has a special interest in the measurement of clinically relevant changes in Alzheimer’s disease and related dementias, and the development and validation of clinical outcome measures. Most of her research relates to the ‘Capturing Changes in Cognition’ (Catch-Cog) project, which is an international, longitudinal cohort study on the measurement of changes in cognition and everyday functioning in early dementia stages. In 2017, Roos obtained a fellowship grant from the Dutch Alzheimer’s Association to perform an off-site research fellowship in the United States of America. During this fellowship, she collaborated with researchers from the University of Rhode Island (Providence, RI) and Massachusetts General Hospital, Harvard Medical School (Boston, MA). In 2017, she joined the Non-pharmacological Interventions PIA Executive Committee as a Student Member, and she is currently has the role of General Member. Next to this, Roos is also a board member of the Dutch Neuropsychological Association, in which she represents Dutch PhD students who work in the field of neuropsychology.
Steering Committee Member: Rhoda Au, PhD
Rhoda Au is Professor of Anatomy & Neurobiology, Neurology and Epidemiology at Boston University Schools of Medicine and Public and is a Senior Fellow at the Institute for Health Systems Innovation and Policy at the Questrom School of Business. She also currently serves as Director of Neuropsychology at the Framingham Heart Study (FHS), where she has been involved in research related to cognitive aging and preclinical/clinical dementia since 1990. Most recently, she has integrated digital technology into the cognitive assessment process while preserving the traditional paper-pencil test experience. Using digital voice and digital pen to capture cognitive performance underlies her current work of determining the potential of digital cognitive biomarkers as surrogate indices to more expensive and invasive fluid and imaging biomarkers. She has also been facilitating the development of a multi-sensory brain health monitoring platform that is customizable, flexibly responsive to the rapidly changing technology landscape and technology agnostic, and scalable. Her objectives include transitioning the platform from reliance on active engagement/high friction technologies to minimal engagement/low friction ones. She is also actively involved in developing broad based data sharing resources to accelerate data science/AI driven discovery of digital biomarkers and novel disease pathways and treatment solutions. Dr. Au is building multi-sector ecosystems to enable strategies for chronic disease prevention generally and optimizing brain health specifically and to move the primary focus of health technologies from precision AD medicine to a broader emphasis on precision brain health.
Steering Committee Member: Ratnavalli Ellajosyula, MD, DM
Dr. Ratnavalli Ellajosyula is a Consultant Neurologist & Specialist in Cognitive Neurology. She did her medical and neurology training from reputed medical schools in New Delhi. She was faculty at the prestigious National Institute of Mental Health & Neurosciences (NIMHANS), Bangalore for 11 years. Subsequently she was the head of department of Neurology at Manipal Hospital, Bangalore where she also initiated the postgraduate training in Neurology. She is the recipient of a Commonwealth Fellowship and did a fellowship in Cognitive and Behavioural Neurology at University of Cambridge, UK under Prof. John Hodges. She was a research fellow at the University of Chapel hill, North Carolina, USA in 2005.
She started the first memory clinic in India in 1998, while at NIMHANS. She now heads the multidisciplinary Cognitive neurology clinic at Manipal Hospital and Annasawmy Mudaliar Hospital, Bangalore and Neurocare clinic, Mysore. This clinic receives referrals from all over India. She received the Gandhi Research Fellowship award in House of Lords, UK in 2016.
Her current research interests are language representation in bilinguals, cognitive reserve and vulnerability, use of cognitive tests as biomarkers and Frontotemporal dementias. Her team has developed a telephone-screening instrument and have experience with brief tests like the visual association test to differentiate mild cognitive impairment from patients with Alzheimer’s disease. She was the recipient of a research grant under the cognitive science research initiative (CSI) by the Department of Science and Technology (DST), Government of India, 2015. Her work has been published in several International Journals. Her first author paper on ’The prevalence of FTD’ in Neurology journal, 2002 has over 1000 citations. She was associate editor for Annals of Indian academy of Neurology. She is a reviewer for several Neurology and Neuropsychology journals.
Dr.Ellajosyula is passionate about teaching and is a faculty and resource person at International and National meetings. She has organized the World Federation of Neurology sponsored teaching course in Cognitive Neurology in India and also the National conference of the Alzheimer’s Disease and Related Disorders Association of India (ARDSI). She was the Joint secretary of the Alzheimer’s Disease and Related Disorders Association of India (ARDSI), Bangalore Chapter. She works closely with several non-governmental organizations voluntarily, in particular Nightingales Medical Trust to raise awareness about dementia and stroke and conducts workshops and training for caregivers, physicians and students on dementia. She is a fellow of the American Academy of Neurology (FAAN) and life member of the Alzheimer disease International, Indian academy of Neurology, Neurology India and a member of Alzheimer Association.
Steering Committee Member: Kathleen Welsh-Bohmer, PhD
Dr. Kathleen Welsh-Bohmer is a Professor of Psychiatry and Neurology at Duke University. Clinically trained as a neuropsychologist, her research activities have been focused around developing effective prevention and treatment strategies to delay the onset of cognitive disorders occurring in later life. She was the Principal Investigator of the Cache County Memory Study (2002-2013), an epidemiological study of an exceptionally longlived population that established key environmental modifiers affecting Alzheimer’s disease onset and progression. Since 2006 she has directed the Joseph and Kathleen Bryan Alzheimer’s Center at Duke University, where she has led a large multidisciplinary team focused around the genetic determinants of Alzheimer’s disease and speeding drug discoveries to prevent and treat neurodegenerative diseases. She has served as the neuropsychology lead for the TOMMORROW program, a global clinical trial to delay the onset of mild cognitive impairment due to Alzheimer’s disease (Takeda Pharmaceutical Company). And very recently, she was appointed to the Duke Clinical Research Institute (DCRI), an academic clinical research organization, to oversee its interventional trials within the Alzheimer’s disease therapeutic area. Concurrently, she is leading science strategy for neurodegenerative disorders in VeraSci, a private company focused on improving the precision of endpoint measurements within clinical trial designs. The methods her team has been developing in collaboration with public and private partners help fill an information void in the measurement of preclinical dementias and has important implications for accelerating global clinical trials in Alzheimer’s disease prevention and in population health.
Chair: Andreas Monsch, PhD
Andreas Monsch received his PhD in 1991 from the University of Zuerich, Switzerland. He then completed a postdoctoral research fellowship with the late Professor Nelson Butters at UC San Diego until 1994. In 1994, Dr. Monsch returned to Switzerland and became director of research at the Memory Clinic of the University Hospital in Basel, Switzerland and was board-certified as a clinical neuropsychologist in 2001. In 2002, he became Head of the Memory Clinic. He joined the faculty of the University of Basel, Switzerland became an honorary professor in 2003.
Dr. Monsch has served and serves on several boards: International Neuropsychological Society (past governor), Swiss Memory Clinics (president 2008-2016), Swiss Association of Neuropsychology (current president), Alzheimer Forum Switzerland (current president). He has also served and serves on a number of Advisory Board of the pharmaceutical industry. Dr. Monsch's research interest focuses on the earliest detection of neurocognitive disorders and on rare causes of dementia. He has published more than 150 research articles and book chapters.